20 studies were found.

1.		Recruiting	Expanded access use of Myozyme (alglucosidase alfa) in patients with infantile-onset Pompe disease Conditions: Glycogen Storage Disease Type II; Glycogenosis 2
2.		Suspended	Expanded Access Use of Myozyme (alglucosidase alfa) in Patients with Late-onset Pompe disease Conditions: Glycogen Storage Disease Type II; Glycogenosis 2
3.		Recruiting	Iron Balance Study of DFO and GT56-252 in Patients with Transfusional Iron Overload Secondary to Beta-Thalassemia Condition: beta-Thalassemia
4.		No longer recruiting	A Prospective, Observational Study in Patients with Late-Onset Pompe Disease Condition: Glycogen Storage Disease Type II
5.		Completed	Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease Conditions: Pompe Disease; Glycogen Storage Disease Type II; Acid Maltase Deficiency Disease; Glycogenosis 2
6.		Completed	Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients with Early Stage Diffuse Systemic Sclerosis Conditions: Systemic Sclerosis; Scleroderma
7.		No longer recruiting	Safety/Efficacy of a Vaccine Prepared from Dendritic Cells combined with Tumor Cells to Treat Advanced Kidney Cancer Condition: Carcinoma, Renal Cell
8.		Recruiting	Study of DENSPM in Patients with Liver Cancer who are Not Eligible for Surgical Cure Condition: Carcinoma, Hepatocellular
9.		No longer recruiting	A Study of Fabrazyme in Pediatric Patients with Fabry Disease Condition: Fabry Disease
10.		Completed	A Study of GT160-246 Versus Vancomycin in Patients with Clostridium difficile-Associated Diarrhea Conditions: Clostridium difficile-Associated Diarrhea; Clostridium Enterocolitis; Clostridium Difficile Diarrhea; Antibiotic-Associated Colitis; ...
11.		Completed	A Study of the Safety and Efficacy of Fabrazyme as Compared to Placebo in Patients with Advanced Fabry Disease Condition: Fabry Disease
12.		No longer recruiting	A Study of the Safety and Efficacy of Fabrazyme in Patients with Fabry Disease Condition: Fabry Disease
13.		No longer recruiting	A Study of the Safety and Efficacy of Fabrazyme in Patients with Fabry Disease Condition: Fabry Disease
14.		No longer recruiting	A study of the safety and efficacy of rhGAA in patients with infantile-onset GSD-II (Pompe disease) Conditions: Glycogen Storage Disease Type II; Pompe Disease; Acid Maltase Deficiency Disease; Glycogenosis 2
15.		No longer recruiting	A Study of the Safety and Efficacy of rhGAA in Patients with Infantile-onset Pompe Disease Condition: Glycogen Storage Disease Type II
16.		Completed	A study of the safety and pharmacokinetics of rhGAA in siblings with Glycogen Storage Disease Type II Conditions: Glycogen Storage Disease Type II; Pompe Disease; Acid Maltase Deficiency Disease; Glycogenosis 2
17.		Recruiting	A Study to Evaluate the Effect of Thymoglobulin on the Prevention of Renal Transplant Rejection Conditions: Renal Transplantation; Graft Rejection
18.		Recruiting	Thymoglobulin to Prevent Acute Graft vs. Host (GvHD) in Patients with Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant Conditions: Acute myelogenous leukemia (AML); Acute lymphocytic leukemia (ALL); Graft vs. Host Disease (GvHD)
19.		No longer recruiting	Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma Conditions: Stage IV Melanoma; stage II melanoma; stage III melanoma
20.		No longer recruiting	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Conditions: Stage IV Melanoma; stage III melanoma; Recurrent Melanoma